Skip to content

Study · In vitro (cells) · rat · 1998

6 results

Thymosin fraction 5 inhibits the proliferation of the rat neuroendocrine MMQ pituitary adenoma and C6 glioma cell lines in vitro.

Spangelo BL, Farrimond DD, Thapa M, Bulathsinghala CM, Bowman KL, Sareh A, Hughes FM Jr, Goldstein AL, Badamchian M

Endocrinology1 Apr 1998Cited by 9 (Europe PMC)

PMID9529005 (opens in a new tab)DOI10.1210/endo.139.4.5935 (opens in a new tab)PepBankPUB-09529005
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01LabIn vitro (cells)Activity measurement

    In rat MMQ pituitary adenoma cells, thymosin alpha1 had no effect on cell proliferation.

    In plain wordsIn rat tumour cells in lab tests, thymosin alpha‑1 alone did not change cell growth.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeMMQ pituitary adenoma cell proliferation
    Study

    ratn: not reported in source

    MMQ rat pituitary adenoma cell line
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The peptides thymosin alpha1 (T alpha1), thymosin beta4 (T beta4), MB35, and MB40 had no effect on either MMQ or C6 cell proliferation, indicating that these TF5 components are not the principle active peptides.
    1 context sentence
    Summary · context
    Cells of the PRL-secreting rat anterior pituitary adenoma, MMQ (5-50 x 10(3) cells/well), were exposed to vehicle (RPMI-1640 containing 2.5% FCS, 7.5% horse serum, and antibiotics) or TF5 (100-500 microg/ml) for up to 96 h and the proliferation of MMQ cells monitored using the MTT assay (3-(4, 5-dim…
  2. 02LabIn vitro (cells)Activity measurement

    In rat C6 glioma cells, thymosin alpha1 had no effect on cell proliferation.

    In plain wordsIn rat tumour cells in lab tests, thymosin alpha‑1 alone did not change cell growth.

    Peptide
    Thymosin alpha-1
    Outcome
    No significant changeC6 glioma cell proliferation
    Study

    ratn: not reported in source

    C6 rat glioma cell line
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The peptides thymosin alpha1 (T alpha1), thymosin beta4 (T beta4), MB35, and MB40 had no effect on either MMQ or C6 cell proliferation, indicating that these TF5 components are not the principle active peptides.
    1 context sentence
    Summary · context
    Cells of the PRL-secreting rat anterior pituitary adenoma, MMQ (5-50 x 10(3) cells/well), were exposed to vehicle (RPMI-1640 containing 2.5% FCS, 7.5% horse serum, and antibiotics) or TF5 (100-500 microg/ml) for up to 96 h and the proliferation of MMQ cells monitored using the MTT assay (3-(4, 5-dim…
  3. 03LabIn vitro (cells)Activity measurement

    In rat MMQ pituitary adenoma and C6 glioma cells, thymosin beta‑4 did not change cell proliferation.

    In plain wordsIn cells from rat tumors, thymosin beta‑4 did not change cell growth.

    Peptide
    Thymosin beta-4 (human)
    Outcome
    No significant changeMMQ and C6 cell proliferation
    Study

    ratn: not reported in source

    MMQ pituitary adenoma and C6 glioma cell lines
    Comparator
    Vehicle
    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The peptides thymosin alpha1 (T alpha1), thymosin beta4 (T beta4), MB35, and MB40 had no effect on either MMQ or C6 cell proliferation
    1 context sentence
    Summary · context
    Cells of the PRL-secreting rat anterior pituitary adenoma, MMQ (5-50 x 10(3) cells/well), were exposed to vehicle (RPMI-1640 containing 2.5% FCS, 7.5% horse serum, and antibiotics) or TF5 (100-500 microg/ml) for up to 96 h and the proliferation of MMQ cells monitored using the MTT assay (3-(4, 5-dim…

Studies that did not test the peptide alone3

In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Thymosin alpha-1.

  1. 04LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In rat MMQ pituitary adenoma cells, thymosin fraction 5 (a bovine thymus preparation) inhibited proliferation in a concentration-dependent way; 500 microg/ml completely blocked cell division.

    In plain wordsIn rat tumour cells in lab tests, a thymus extract mixture stopped cell growth.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseMMQ cell proliferation with thymosin fraction 5
    Study

    ratn: not reported in source

    MMQ rat pituitary adenoma cell line
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Minimal reductions in optical densities resulted from exposure to 100 microg/ml TF5, whereas the highest concentration of this preparation (i.e. 500 microg/ml) completely blocked MMQ cell division.
    1 context sentence
    Summary · context
    Cells of the PRL-secreting rat anterior pituitary adenoma, MMQ (5-50 x 10(3) cells/well), were exposed to vehicle (RPMI-1640 containing 2.5% FCS, 7.5% horse serum, and antibiotics) or TF5 (100-500 microg/ml) for up to 96 h and the proliferation of MMQ cells monitored using the MTT assay (3-(4, 5-dim…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  2. 05LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Activity measurement

    In rat C6 glioma cells, thymosin fraction 5 (a bovine thymus preparation) inhibited proliferation at concentrations as low as 10 microg/ml.

    In plain wordsIn rat tumour cells in lab tests, a thymus extract mixture reduced cell growth.

    Peptide
    Thymosin alpha-1
    Outcome
    DecreaseC6 glioma cell proliferation with thymosin fraction 5
    Study

    ratn: not reported in source

    C6 rat glioma cell line
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    concentrations as low as 10 microg/ml TF5 inhibited C6 cell proliferation (P < 0.01), and near-maximal inhibition was noted at 200 microg/ml TF5.
    1 context sentence
    Summary · context
    Cells of the PRL-secreting rat anterior pituitary adenoma, MMQ (5-50 x 10(3) cells/well), were exposed to vehicle (RPMI-1640 containing 2.5% FCS, 7.5% horse serum, and antibiotics) or TF5 (100-500 microg/ml) for up to 96 h and the proliferation of MMQ cells monitored using the MTT assay (3-(4, 5-dim…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

  3. 06LabNot a test of Thymosin alpha-1 aloneIn vitro (cells)Mechanism

    In rat MMQ and C6 cells, thymosin fraction 5 reduced cell viability and the cells died by apoptosis.

    In plain wordsIn rat tumour cells in lab tests, a thymus extract mixture made cells die by programmed cell death.

    Peptide
    Thymosin alpha-1
    Outcome
    IncreaseApoptosis in MMQ and C6 cells with thymosin fraction 5
    Study

    ratn: not reported in source

    MMQ and C6 rat cell lines
    Outcome group
    Tumor growth · Cancer

    Source sentences

    Summary
    Significant reductions in MMQ and C6 cell viabilities accompanied decreases in cell number and morphological analysis indicated these cells were dying by apoptosis.
    1 context sentence
    Summary · context
    Cells of the PRL-secreting rat anterior pituitary adenoma, MMQ (5-50 x 10(3) cells/well), were exposed to vehicle (RPMI-1640 containing 2.5% FCS, 7.5% horse serum, and antibiotics) or TF5 (100-500 microg/ml) for up to 96 h and the proliferation of MMQ cells monitored using the MTT assay (3-(4, 5-dim…

    In this study, Thymosin alpha-1 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Thymosin alpha-1.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    12 Oct 2026, 18:17 UTC

    Study data updated · source update from Europe PMC

  2. Version 3

    10 Oct 2026, 08:55 UTC

    Study results updated

  3. Version 2

    9 Oct 2026, 03:03 UTC

    Study data updated · source update from Europe PMC

  4. Version 1

    9 Oct 2026, 03:02 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.